观点：类风湿关节炎治疗中糖皮质激素的应用：值得（重新）思考的要点。
Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider.
机构信息
Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
出版信息
Rheumatology (Oxford). 2023 Nov 2;62(11):3534-3537. doi: 10.1093/rheumatology/kead309.
Abstract
Glucocorticoids (prednisone) are essential in the treatment of RA and other autoimmune diseases. They are widely used, but treatment guidelines advise against. This viewpoint article explains why and suggests a way forward.
摘要
糖皮质激素（泼尼松）是治疗类风湿关节炎和其他自身免疫性疾病的重要药物。它们被广泛应用，但治疗指南建议避免使用。本文观点性文章解释了其中的原因，并提出了前进的方向。
相似文献
1
Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider.观点：类风湿关节炎治疗中糖皮质激素的应用：值得（重新）思考的要点。
Rheumatology (Oxford). 2023 Nov 2;62(11):3534-3537. doi: 10.1093/rheumatology/kead309.
2
Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years.糖皮质激素治疗类风湿关节炎：65 岁后仍在使用。
Ann N Y Acad Sci. 2014 May;1318:27-31. doi: 10.1111/nyas.12394. Epub 2014 Mar 18.
3
Rheumatoid arthritis: Methotrexate and bridging glucocorticoids in early RA.类风湿关节炎：早期类风湿关节炎中的甲氨蝶呤和桥接糖皮质激素
Nat Rev Rheumatol. 2014 Dec;10(12):698. doi: 10.1038/nrrheum.2014.197. Epub 2014 Nov 11.
4
Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.托珠单抗与泼尼松相比在对改善病情抗风湿药反应不足的类风湿关节炎患者中的有效性（TOPIRA）：一项实用试验的研究方案
Trials. 2020 Apr 5;21(1):313. doi: 10.1186/s13063-020-04260-y.
5
[Prednisone for rheumatoid arthritis: the detriment of the doubt].[用于类风湿性关节炎的泼尼松：存疑的危害]
Ned Tijdschr Geneeskd. 2012;155(32):A5069.
6
Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.评论：在临床实践中，托珠单抗可减少类风湿关节炎患者的皮质类固醇用量。
Rheumatology (Oxford). 2015 Apr;54(4):751. doi: 10.1093/rheumatology/keu467. Epub 2015 Jan 19.
7
Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice: reply.关于《托珠单抗在临床实践中可减少类风湿关节炎患者的皮质类固醇用量：回复》的评论
Rheumatology (Oxford). 2015 Apr;54(4):751-2. doi: 10.1093/rheumatology/keu468. Epub 2015 Jan 19.
8
A fresh look at glucocorticoids how to use an old ally more effectively.重新审视糖皮质激素：如何更有效地利用这个老盟友。
Bull NYU Hosp Jt Dis. 2012;70 Suppl 1:26-9.
9
The Story Behind the Use of Glucocorticoids in the Treatment of Rheumatoid Arthritis.糖皮质激素治疗类风湿关节炎的背后故事。
Semin Arthritis Rheum. 2021 Feb;51(1):15-19. doi: 10.1016/j.semarthrit.2020.09.016. Epub 2020 Dec 17.
10
[2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis].《2018年中国类风湿关节炎诊疗指南》
Zhonghua Nei Ke Za Zhi. 2018 Apr 1;57(4):242-251. doi: 10.3760/cma.j.issn.0578-1426.2018.04.004.
引用本文的文献
1
Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects.类风湿性关节炎与心血管疾病的相互作用：见解与展望。
SAGE Open Med. 2025 Jul 23;13:20503121251330171. doi: 10.1177/20503121251330171. eCollection 2025.
2
Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets.自身免疫性疾病：分子发病机制与治疗靶点
MedComm (2020). 2025 Jun 16;6(7):e70262. doi: 10.1002/mco2.70262. eCollection 2025 Jul.
3
Prevalence of Various Systemic and Organ-Specific Autoimmune Markers in Addison's Disease Patients Compared to Healthy Controls.与健康对照相比，艾迪生病患者各种全身性和器官特异性自身免疫标志物的患病率。
J Clin Med. 2025 Jun 3;14(11):3951. doi: 10.3390/jcm14113951.
本文引用的文献
1
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.在 GLORIA 试验之后进行安慰剂对照的双盲减量：高龄类风湿关节炎患者中，长程低剂量糖皮质激素 3 个月减量和停药是可行和安全的。
Ann Rheum Dis. 2023 Oct;82(10):1307-1314. doi: 10.1136/ard-2023-223977. Epub 2023 Aug 4.
2
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?我们会在使用低剂量糖皮质激素治疗类风湿关节炎的问题上达成共识吗？
Rheumatology (Oxford). 2023 Aug 1;62(8):2635-2636. doi: 10.1093/rheumatology/kead167.
3
Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.长期低剂量糖皮质激素治疗类风湿关节炎的安全性和疗效：系统评价和荟萃分析。
Rheumatology (Oxford). 2023 Aug 1;62(8):2652-2660. doi: 10.1093/rheumatology/kead088.
4
Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.类风湿关节炎患者桥接治疗起始后继续使用糖皮质激素的个体化患者数据荟萃分析。
Ann Rheum Dis. 2023 Apr;82(4):468-475. doi: 10.1136/ard-2022-223443. Epub 2022 Dec 16.
5
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.糖皮质激素的疗效、使用时长及安全性：一项系统性文献综述，为2022年欧洲抗风湿病联盟类风湿关节炎管理推荐的更新提供依据
Ann Rheum Dis. 2023 Jan;82(1):81-94. doi: 10.1136/ard-2022-223358. Epub 2022 Nov 21.
6
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.EULAR 推荐的类风湿关节炎治疗方案：使用合成和生物疾病修正抗风湿药物：2022 更新版。
Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.
7
Three Months of Glucocorticoids in Rheumatoid Arthritis: A Bridge Too Short?类风湿关节炎中使用糖皮质激素三个月：时间太短了吗？
Arthritis Rheumatol. 2022 Oct;74(10):1609-1611. doi: 10.1002/art.42249. Epub 2022 Aug 22.
8
The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial.短期高、低剂量泼尼松桥接治疗方案对活动期早期类风湿关节炎影像学和临床结局的疗效：一项双盲、随机、安慰剂对照试验。
Arthritis Rheumatol. 2022 Oct;74(10):1628-1637. doi: 10.1002/art.42245.
9
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.65 岁及以上类风湿关节炎患者中低剂量、附加泼尼松龙治疗：实用随机、双盲安慰剂对照 GLORIA 试验。
Ann Rheum Dis. 2022 Jul;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957. Epub 2022 May 31.
10
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis.系统性文献综述观察队列和临床试验，评估在类风湿关节炎患者中使用糖皮质激素桥接治疗后停药成功率。
Ann Rheum Dis. 2022 Jul;81(7):937-943. doi: 10.1136/annrheumdis-2022-222338. Epub 2022 Apr 25.
Zotero 插件